Overview

A Phase 3 Extension Study to Investigate the Long-term Safety, Tolerability and Efficacy of PA21, a Phosphate Binder in Dialysis Patients

Status:
Completed

Trial end date:
2013-04-01

Target enrollment:

Participant gender:

Summary

This is a Phase 3, randomised, active controlled, multicentre extension study to investigate the long-term safety and efficacy of PA21, a phosphate binder, for control of hyperphosphataemia in dialysis patients. This is an extension study to PA-CL-05A (NCT01324128), subjects have already been enrolled and have been treated with study medication for at least 24 weeks.

Phase:

Phase 3

Details

Lead Sponsor:

Vifor Inc.
Vifor Pharma

Collaborator:

Fresenius Medical Care North America

Treatments:

Sevelamer